Literature DB >> 33684598

Motor cortex transcranial direct current stimulation effects on knee osteoarthritis pain in elderly subjects with dysfunctional descending pain inhibitory system: A randomized controlled trial.

Daniela Regina Brandão Tavares1, Jane Erika Frazao Okazaki2, Marcia Valéria de Andrade Santana3, Ana Carolina Pereira Nunes Pinto4, Karina Kuraoka Tutiya5, Fernanda Martins Gazoni6, Camila Bonin Pinto7, Fania Cristina Santos8, Felipe Fregni9, Virginia Fernandes Moça Trevisani10.   

Abstract

BACKGROUND: Although evidence has indicated a positive effect of transcranial direct current stimulation (tDCS) on reducing pain, few studies have focused on the elderly population with knee osteoarthritis (KOA).
OBJECTIVE: To evaluate whether tDCS reduces KOA pain in elderly individuals with a dysfunctional descending pain inhibitory system (DPIS).
METHODS: In a double-blind trial, individuals ≥ 60 years with KOA pain and a dysfunctional DPIS, we randomly assigned patients to receive 15 daily sessions of 2 mA tDCS over the primary motor cortex (anode) and contralateral supraorbital area (cathode) (M1-SO) for 20 min or sham tDCS. Change in pain perception indexed by the Brief Pain Inventory (BPI) at the end of intervention was the primary outcome. Secondary outcomes included: disability, quantitative sensory testing, pain pressure threshold and conditioned pain modulation (CPM). Subjects were followed-up for 2 months.
RESULTS: Of the 104 enrolled subjects, with mean (SD) age of 73.9 (8.01) years and 88 (84.6%) female, 102 finished the trial. In the intention-to-treat analysis, the active tDCS group had a significantly greater reduction in BPI compared to the sham group (difference, 1.59; 95% CI, 0.95 to 2.23; P < 0.001; Cohen's d, 0.58); and, also a significantly greater improvement in CPM-pressure in the knee (P = 0.01) and CPM-pain in the hand (P = 0.01). These effects were not sustained at follow-up. The intervention was well tolerated, with no severe adverse effects.
CONCLUSION: M1-SO tDCS is associated with a moderate effect size in reducing pain in elderly patients with KOA after 15 daily sessions of stimulation. This intervention has also shown to modulate the DPIS.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Central sensitization; Chronic pain; Conditioned pain modulation; Elderly; Knee osteoarthritis; Transcranial direct current stimulation

Year:  2021        PMID: 33684598     DOI: 10.1016/j.brs.2021.02.018

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  5 in total

1.  Relieving Chronic Musculoskeletal Pain in Older Adults Using Transcranial Direct Current Stimulation: Effects on Pain Intensity, Quality, and Pain-Related Outcomes.

Authors:  Marie-Philippe Harvey; Marylie Martel; Francis Houde; Inès Daguet; Eléonor Riesco; Guillaume Léonard
Journal:  Front Pain Res (Lausanne)       Date:  2022-04-14

2.  Scientific Knowledge Graph and Trend Analysis of Central Sensitization: A Bibliometric Analysis.

Authors:  Zhuo Li; Chi Xu; Jun Fu; Maimaiti Zulipikaer; Tao Deng; Jiying Chen
Journal:  J Pain Res       Date:  2022-02-24       Impact factor: 3.133

3.  Self-administered transcranial direct current stimulation for pain in older adults with knee osteoarthritis: A randomized controlled study.

Authors:  Geraldine Martorella; Kenneth Mathis; Hongyu Miao; Duo Wang; Lindsey Park; Hyochol Ahn
Journal:  Brain Stimul       Date:  2022-06-08       Impact factor: 9.184

4.  Efficacy of Home-Based Transcranial Direct Current Stimulation on Experimental Pain Sensitivity in Older Adults with Knee Osteoarthritis: A Randomized, Sham-Controlled Clinical Trial.

Authors:  Geraldine Martorella; Kenneth Mathis; Hongyu Miao; Duo Wang; Lindsey Park; Hyochol Ahn
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

Review 5.  Non-invasive brain stimulation for osteoarthritis.

Authors:  Hui-Qi Zhu; Jing Luo; Xue-Qiang Wang; Xin-An Zhang
Journal:  Front Aging Neurosci       Date:  2022-09-29       Impact factor: 5.702

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.